{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:11:07Z","timestamp":1780567867626,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clineuro.2025.109111","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:23:04Z","timestamp":1755040984000},"page":"109111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Repeated MRI-negative demyelinating attacks linked to MOG-IgG antibodies and silent lesions \u2013 Case series and literature review"],"prefix":"10.1016","volume":"257","author":[{"given":"Tal","family":"Friedman-Korn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-3576","authenticated-orcid":false,"given":"Ariel","family":"Rechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Zveik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2025.109111_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges","author":"Al-Ani","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein Antibody-Associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib4","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1177\/1352458519837705","article-title":"MOG antibody\u2013associated encephalomyelitis\/encephalitis","volume":"25","author":"Salama","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.clineuro.2025.109111_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/acn3.51759","article-title":"Attack phenotypes and disease course in pediatric MOGAD","volume":"10","author":"Santoro","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib6","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.109111_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.26793","article-title":"Myelin oligodendrocyte glycoprotein antibodies in adults with a first demyelinating event suggestive of multiple sclerosis","volume":"95","author":"Villacieros-\u00c1lvarez","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib9","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/brain\/awac480","article-title":"Clinical and MRI measures to identify non-acute MOG-antibody disease in adults","volume":"146","author":"Cortese","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2025.109111_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cei.13641","article-title":"Clinical and neuroimaging findings in MOGAD\u2013MRI and OCT","volume":"206","author":"Bartels","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clineuro.2025.109111_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-332542","article-title":"UK-Childhood neuroinflammatory disease network, evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","author":"Abdel-Mannan","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2025.109111_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2025.109111_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2025.109111_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209156","article-title":"Trans-Synaptic degeneration in the visual pathway in patients with myelin oligodendrocyte glycoprotein Antibody-Associated disease","volume":"102","author":"Bollo","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.109111_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein Antibody\u2013Positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.clineuro.2025.109111_bib16","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1212\/WNL.0000000000207478","article-title":"Timing and predictors of T2-Lesion resolution in patients with myelin oligodendrocyte glycoprotein Antibody-Associated disease","volume":"101","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.109111_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1210972","article-title":"Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"14","author":"Perez-Giraldo","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Japan MOG-antibody disease consortium, myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2025.109111_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/jon.13137","article-title":"MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease","author":"Carnero Contentti","year":"2023","journal-title":"J. Neuroimaging"},{"key":"10.1016\/j.clineuro.2025.109111_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/08820538.2020.1866027","article-title":"MRI characteristics of NMO, MOG and MS related optic neuritis","volume":"35","author":"Winter","year":"2020","journal-title":"Semin Ophthalmol."},{"key":"10.1016\/j.clineuro.2025.109111_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib22","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1007\/s00415-024-12438-6","article-title":"Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings","volume":"271","author":"Rechtman","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin g (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib24","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1007\/s00415-024-12666-w","article-title":"Rapid differentiation of MOGAD and MS after a single optic neuritis","volume":"271","author":"Pakeerathan","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jnnp.2008.144121","article-title":"Myelopathy but normal MRI: where next?","volume":"8","author":"Wong","year":"2008","journal-title":"Pr. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib26","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jacr.2021.01.020","article-title":"ACR appropriateness Criteria\u00ae myelopathy: 2021 update","volume":"18","author":"Agarwal","year":"2021","journal-title":"J. Am. Coll. Radiol."},{"key":"10.1016\/j.clineuro.2025.109111_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clineuro.2025.109111_bib28","first-page":"709","article-title":"Myelopathies secondary to Sj\u00f6gren\u2019s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids","volume":"33","author":"de Seze","year":"2006","journal-title":"J. Rheuma"},{"key":"10.1016\/j.clineuro.2025.109111_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.59.2.120","article-title":"Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature","volume":"59","author":"Kovacs","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clineuro.2025.109111_bib30","first-page":"467","article-title":"Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome","volume":"25","author":"Mok","year":"1998","journal-title":"J. Rheuma"},{"key":"10.1016\/j.clineuro.2025.109111_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106513","article-title":"Late-onset rapidly progressive MRI- negative-myelitis after COVID-19 illness","volume":"202","author":"Memon","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.clineuro.2025.109111_bib32","first-page":"1","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","author":"Sechi","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.clineuro.2025.109111_bib33","doi-asserted-by":"crossref","DOI":"10.17161\/rrnmf.v6i1.21721","article-title":"Diagnostic and treatment challenges in MRI-negative myelitis associated with MOG antibody: a case report and literature review","volume":"6","author":"Ortiz-Guerrero","year":"2025","journal-title":"Rrnmf"},{"key":"10.1016\/j.clineuro.2025.109111_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458519840746","article-title":"MOG-related disorders: a new cause of imaging-negative myelitis?","volume":"26","author":"Macaron","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2025.109111_bib35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3988\/jcn.2022.0433","article-title":"A case of MRI-negative encephalomyelitis in a patient with long-term stable myelin oligodendrocyte glycoprotein Antibody-Associated disease","volume":"19","author":"Hwangbo","year":"2023","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib36","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ncn3.12544","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody-associated disease presenting MRI-negative myelitis and papilledema","volume":"9","author":"Goto","year":"2021","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.clineuro.2025.109111_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12883-022-02837-5","article-title":"Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report","volume":"22","author":"Kolcava","year":"2022","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2023.100481","article-title":"MRI-negative myelitis associated with MOG-IgG antibody: a case report and literature reviews","volume":"33","author":"Yang","year":"2023","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.clineuro.2025.109111_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X19830475","article-title":"MRI-Negative myelitis associated with myelin oligodendrocyte glycoprotein antibody spectrum demyelinating disease","volume":"6","author":"P\u00e9rez","year":"2019","journal-title":"Child Neurol. Open"},{"key":"10.1016\/j.clineuro.2025.109111_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00415-019-09591-8","article-title":"3D PSIR MRI at 3 tesla improves detection of spinal cord lesions in multiple sclerosis","volume":"267","author":"Mirafzal","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247813","article-title":"3D-Fast gray matter acquisition with phase sensitive inversion recovery magnetic resonance imaging at 3 tesla: application for detection of spinal cord lesions in patients with multiple sclerosis","volume":"16","author":"Goujon","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clineuro.2025.109111_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3174\/ajnr.A5941","article-title":"A 3T Phase-Sensitive inversion recovery MRI sequence improves detection of cervical spinal cord lesions and shows active lesions in patients with multiple sclerosis","volume":"40","author":"Fechner","year":"2019","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.clineuro.2025.109111_bib43","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3174\/ajnr.A3637","article-title":"Optimized T1-MPRAGE sequence for better visualization of spinal cord multiple sclerosis lesions at 3T","volume":"34","author":"Nair","year":"2013","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.clineuro.2025.109111_bib44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ane.12168","article-title":"A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions","volume":"129","author":"Nayak","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clineuro.2025.109111_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00586-010-1587-3","article-title":"Diffusion tensor imaging in the cervical spinal cord","volume":"20","author":"Song","year":"2011","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.clineuro.2025.109111_bib46","series-title":"Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes, JAMA Netw Open","author":"Fadda","year":"2021"},{"key":"10.1016\/j.clineuro.2025.109111_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and Aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.clineuro.2025.109111_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2025-336684","article-title":"MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis","author":"Syc-Mazurek","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2025.109111_bib51","first-page":"426","article-title":"Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","volume":"95","author":"Abdel-mannan","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2025.109111_bib52","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2025-336684","article-title":"MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis","author":"Syc-Mazurek","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2025.109111_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577702","article-title":"Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder","volume":"360","author":"Molazadeh","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2025.109111_bib55","unstructured":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome | Journal of Neuroinflammation, (n.d.). \u3008https:\/\/link.springer.com\/article\/10.1186\/s12974-016-0718-0\u3009 (Accessed July 24, 2025)."},{"key":"10.1016\/j.clineuro.2025.109111_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01157","article-title":"Brain atrophy in relapsing optic neuritis is associated with crion phenotype","volume":"10","author":"Cant\u00f3","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2025.109111_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.867190","article-title":"Volumetric brain loss correlates with a relapsing MOGAD disease course","volume":"13","author":"Rechtman","year":"2022","journal-title":"Front. Neurol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725003944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725003944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:17:48Z","timestamp":1757074668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725003944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S0303846725003944"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109111","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated MRI-negative demyelinating attacks linked to MOG-IgG antibodies and silent lesions \u2013 Case series and literature review","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109111"}}